Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DDO | Q99489 | 1/20 | 0.42 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.40 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.40 |
| ▸ | GRIK5 | Q16478 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10823650 | 0.84 | KMT2A (0.53) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL31282172 | 0.84 | KMT2A (0.49) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL18640363 | 0.81 | KMT2A (0.50) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL425895 | 0.80 | KMT2A (0.49) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL10823643 | 0.80 | HTT (0.56) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL11239615 | 0.78 | CYP2C19 (0.69) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL11238675 | 0.76 | CYP2C19 (0.79) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL5983288 | 0.75 | KMT2A (0.44) | KMT2ACYP2C9MAPTHTTCYP1A2 | |
| SCHEMBL827876 | 0.73 | LMNA (0.58) | KMT2AMAPTCYP1A2GRIA1GRIA2 | |
| SCHEMBL8672229 | 0.73 | KMT2A (0.45) | KMT2ACYP2C9MAPTHTTCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 317 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106695-A1 | TARGETED NANOPARTICLES ENCAPSULATING WATER-SOLUBLE THERAPEUTICS, METHODS OF PRODUCTION, AND USE | OPTIMEOS LIFE SCIENCES, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026098357-A1 | FREEZE-DRIED NUCLEIC ACID-LOADED LIPID NANOPARTICLE AND RECONSTITUTION METHOD THEREOF | KUDO BIOTECHNOLOGY, INC. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260130987-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | PFIZER INC. (US) | 2026-05-14 | — | — | US | disclosed |
| WO-2026088119-A1 | LIPIDATED TLR7/8 MODULATORS AS ADJUVANTS AND USES THEREOF | PFIZER INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | TRILINK BIOTECHNOLOGIES, LLC (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4728076-A1 | METHOD FOR STABILIZING RNA | Pfizer Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4729614-A1 | SYSTEM AND METHOD FOR SEPARATING MRNA | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2026-04-22 | — | — | EP | disclosed |
| EP-4720094-A1 | MUTATED FRAGMENT OF VZV GLYCOPROTEIN E | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2026-04-08 | — | — | EP | disclosed |
| US-12594242-B2 | Lipid compounds and lipid nanoparticle compositions | Suzhou Abogen Biosciences Co., Ltd. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX INC (US) | 2026-03-19 | — | — | US | disclosed |
| WO-2017066791-A1 | SUGAR SUBSTITUTED MRNA CAP ANALOGS | MODERNATX, INC. (US) | 2017-04-20 | — | — | WO | disclosed |
| WO-2017049286-A1 | POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049275-A2 | POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION | MODERNA THERAPEUTICS, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| WO-2017049245-A2 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | MODERNATX, INC. (US) | 2017-03-23 | — | — | WO | disclosed |
| US-7329649-B2 | Combinatorial methods for inducing cancer cell death | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2008-02-12 | — | — | US | disclosed |
| US-20070293453-A1 | Combinatorial Methods For Inducing Cancer Cell Death | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2007-12-20 | — | — | US | disclosed |
| US-20040191223-A1 | Combinatorial methods for inducing cancer cell death | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-09-30 | — | — | US | disclosed |
| EP-1425399-A2 | COMBINATORIAL METHODS FOR INDUCING CANCER CELL DEATH | The Trustees of Columbia University in the City of New York (US) | 2004-06-09 | — | — | EP | disclosed |
| US-20030082140-A1 | Combinatorial methods for inducing cancer cell death | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-05-01 | — | — | US | disclosed |
| WO-2003016499-A2 | COMBINATORIAL METHODS FOR INDUCING CANCER CELL DEATH | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2003-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260109977-A1 | MODIFIED RNA FOR INCREASING PROTEIN EXPRESSION | RNGTT, RNMT, UPF1 | KMT2A 1224/4885CYP2C9 4297/4885MAPT 1867/4885 |
| US-20260130987-A1 | VACCINATION AGAINST PNEUMOCCOCAL AND COVID-19 INFECTIONS | SARS1, CD14, PYCARD | KMT2A 4478/4885CYP2C9 1589/4885MAPT 929/4885 |
| US-12594242-B2 | Lipid compounds and lipid nanoparticle compositions | NPC1, NPC1L1, PLIN3 | KMT2A 2276/4885CYP2C9 862/4885MAPT 3750/4885 |
| US-20260078082-A1 | COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS | PHOSPHO1, LIPC, SDCBP | KMT2A 4212/4885CYP2C9 4775/4885MAPT 2007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.